Clinical Trial Update: XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating XP-102 in combination with trametinib for BRAF V600-mutant advanced solid tumors; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Thyroid Cancer

Drugs mentioned

• Trametinib (trametinib)
• XP-102

Snippet

Sponsor: Xynomic Pharmaceuticals, Inc. | Conditions: Cancer, BRAF V600 Mutation | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING